BTAI icon

BioXcel Therapeutics
BTAI

Overview Fund Activity

43 hedge funds and large institutions have $63.3M invested in BioXcel Therapeutics in 2019 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 18 increasing their positions, 7 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
43
Holders Change
-1
Holders Change %
-2.27%
% of All Funds
0.85%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
18
Reduced
7
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BlackRock
1
BlackRock
New York
$5.85M
2
DAM
2
DLD Asset Management
New York
$956K
3
Point72 Asset Management
3
Point72 Asset Management
Connecticut
$3.73M
4
BFM
4
Boothbay Fund Management
New York
$384K
5
OAM
5
Oxford Asset Management
United Kingdom
$281K

Top Sellers

1
AIM
1
Artemis Investment Management
United Kingdom
$15.5M
2
CH
2
CVI Holdings
Delaware
$0
3
DCM
3
DAFNA Capital Management
California
$0
4
Squarepoint
4
Squarepoint
New York
$338K
5
RA
5
Rational Advisors
New York
$0
Name Holding Trade Value Shares
Change 		Shares
Change %
GWM
51
Geneos Wealth Management
Colorado
– -$1K -13 Closed
CSS
52
Cubist Systematic Strategies
Connecticut
– -$1K -13 Closed
AIC
53
Ameritas Investment Company
Nebraska
– -$1K -5 Closed
1 2
3